• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [18582 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)
2022     NIHR Health Technology Assessment programme SurgiCal Obesity Treatment Study (SCOTS)
2022     NIHR Health Technology Assessment programme Multicentre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD)
2022     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial and economic evaluation of family therapy vs. treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial
2022     NIHR Health Technology Assessment programme Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomized controlled trial. PEXIVAS
2022     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2022     NIHR Health Technology Assessment programme Exercise to prevent shoulder conditions in patients undergoing breast cancer treatment. The PRevention Of Shoulder Problems Study (PROSPER)
2022     NIHR Health Technology Assessment programme Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC PC)
2022     NIHR Health Technology Assessment programme Evaluation of the Healthy Start Voucher Scheme in UK: a natural experiment using the Growing Up in Scotland record linkage study and the Infant Feeding Survey
2022     NIHR Health Technology Assessment programme DexEnceph- Dexamethasone in Herpes Simplex Virus Encephalitis Randomised Controlled Trial and NonHSV Cohort Study
2022     NIHR Health Technology Assessment programme The Best Services Trial (BeST?): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health
2022     NIHR Health Technology Assessment programme Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors (GBS2)
2022     NIHR Health Technology Assessment programme Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access: The PAVE Trial. A multicentre double-blind randomised controlled trial in haemodialysis patients with a stenosis in a native arteriovenous fistula
2022     NIHR Health Technology Assessment programme Assessing the efficacy and safety of methotrexate vs ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema in children Taskforce (TREAT) randomised controlled trial
2022     NIHR Health Technology Assessment programme Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation (LiverTOL-Dx Trial)
2022     NIHR Health Technology Assessment programme Unspecified living kidney donation in the UK: barriers to implementation and delivery
2022     NIHR Health Technology Assessment programme Delivering primary health care to homeless people: an evaluation of the integration, effectiveness and costs of different models
2022     NIHR Health Technology Assessment programme The START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the effectiveness of a manual based coping strategy programme in promoting the mental health of carers of people with dementia - cohort follow-up
2022     NIHR Health Technology Assessment programme Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): a randomised placebo-controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
2022     NIHR Health Technology Assessment programme REVascularisation of Ischaemic VEntricular Dysfunction (REVIVED): a randomised comparison of percutaneous coronary intervention (with optimal medical therapy) vs. optimal medical therapy alone for heart failure secondary to coronary disease
2022     NIHR Health Technology Assessment programme Improving the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography (Perfusion CT)
2022     NIHR Health Technology Assessment programme Enhancing social-emotional health and wellbeing in the early years: a community-based randomised controlled trial (and economic) evaluation of the Incredible Years Infant and Toddler (0-2) Parenting Programmes
2022     NIHR Health Technology Assessment programme Development and evaluation of machine learning methods in whole body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer (MAchine Learning In whole Body Oncology, MALIBO)
2022     NIHR Health Technology Assessment programme FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the Effect on quality of life
2022     NIHR Health Technology Assessment programme A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
2022     NIHR Health Technology Assessment programme Fast-Forward: a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in women with early breast cancer
2022     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2022     NIHR Health Technology Assessment programme Gastric Bypass, adjustable gastric Banding or Sleeve gastrectomy surgery to treat severe and complex obesity: a multi-centre randomised controlled trial (The By-Band-Sleeve Study)
2022     NIHR Health Technology Assessment programme POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes
2022     NIHR Health Technology Assessment programme The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022     NIHR Health Technology Assessment programme E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022     NIHR Health Technology Assessment programme Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2022     NIHR Health Technology Assessment programme RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022     NIHR Health Technology Assessment programme Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodules
2022     NIHR Health Technology Assessment programme Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial (HEAT)
2022     NIHR Health Technology Assessment programme The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome
2022     NIHR Health Technology Assessment programme Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022     NIHR Health Technology Assessment programme Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment
2022     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease
2022     NIHR Health Technology Assessment programme VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot. The VIOLET Study
2022     NIHR Health Technology Assessment programme Liaison Psychiatry: Measurement And Evaluation of Service Types, Referral patterns and Outcomes LP-MAESTRO
2022     NIHR Health Technology Assessment programme Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial
2022     NIHR Health Technology Assessment programme Comparison of ALitretinoin with PUVA as the first line treatment in patients with severe chronic HAnd eczema (ALPHA trial)
2022     NIHR Health Technology Assessment programme Early detection of neovascular age-related macular degeneration
2022     NIHR Health Technology Assessment programme Intravenous immunoglobulin in the management of encephalitis in children
2022     NIHR Health Technology Assessment programme Catheter Ablation versus thoracoscopic Surgical Ablation in long standing persistent Atrial Fibrillation (CASA-AF)
2022     NIHR Health Technology Assessment programme The effectiveness of adjunctive medication management and contingency management to enhance adherence to medications for relapse prevention in alcohol dependence
2022     NIHR Health Technology Assessment programme Cerclage Suture Type for an Insufficient Cervix and its effect on Health outcomes (C-STICH)
2022     NIHR Health Technology Assessment programme At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK (ARRISA-UK): a pragmatic cluster randomised trial with nested economic and process evaluations examining the effects of integrating at-risk asthma registers into primary care with internet-based training and support
2022     NIHR Health Technology Assessment programme StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): A randomised, double-masked, sham- controlled, clinical trial comparing low-voltage X-ray irradiation with as needed ranibizumab, to as needed ranibizumab monotherapy
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Mobility aids for people with physical disabilities
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of diastasis recti
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Return to work – persons with long-term sickleave or welfare recipients
2022     NIHR Health Technology Assessment programme Therapeutic Interventions for Stones of the Ureter (TISU): a multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic retrieval, for ureteric stones
2022     NIHR Health Technology Assessment programme TARGIT-B: An international randomised controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence
2022     NIHR Health Technology Assessment programme PUMA - Paediatric early warning system (PEWS): Utilisation and Mortality Avoidance. A prospective, mixed methods, before and after study identifying the evidence base for the core components of an effective PEWS and the development of an implementation package for implementation and use in the UK
2022     NIHR Health Technology Assessment programme Male synthetic sling versus Artificial urinary Sphincter Trial for men with urodynamic stress incontinence after prostate surgery: Evaluation by Randomised controlled trial (MASTER)
2022     NIHR Health Technology Assessment programme The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial
2022     NIHR Health Technology Assessment programme Mammographic surveillance in breast cancer patients aged 50 years or older
2022     NIHR Health Technology Assessment programme PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Progestogen Therapy
2022     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease: a prospective longitudinal study in a multiethnic population
2022     NIHR Health Technology Assessment programme Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
2022     NIHR Health Technology Assessment programme Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest (Airways-2)
2022     NIHR Health Technology Assessment programme The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury
2022     Swiss Federal Office of Public Health (FOPH) Denosumab (Prolia®) for the treatment of osteoporosis
2022     Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022     Swiss Federal Office of Public Health (FOPH) Levothyroxine as a treatment for subclinical hypothyroidism
2022     Norwegian Institute of Public Health (NIPH) [Transperineal biopsy compared with transrectal biopsy in suspected prostate cancer: protocol for health technology assessment]
2022     NIHR Health Technology Assessment programme Effective Treatments for Thoracic Aortic Aneurysms (ETTAA study): a prospective cohort study
2022     NIHR Health Technology Assessment programme A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson's disease (PD MED)
2022     NIHR Health Technology Assessment programme Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022     NIHR Health Technology Assessment programme Pre-eclampsia in Hospital: Early Induction or Expectant management (PHOENIX)
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Post covid - treatment and rehabilitation. Living review.
2022     NIHR Health Technology Assessment programme Health-Related Quality of Life in two treatment pathways for newly diagnosed open angle glaucoma and ocular hypertension: an unmasked, multi-centre, randomised controlled trial of initial selective laser trabeculoplasty versus conventional medical therapy
2022     NIHR Health Technology Assessment programme HALT-IT trial (Haemorrhage Alleviation with Tranexamic acid Intestinal System), a large randomised placebo controlled trial among patients with acute gastrointestinal haemorrhage of the effects of tranexamic acid on death and transfusion requirement
2022     NIHR Health Technology Assessment programme Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study
2022     NIHR Health Technology Assessment programme Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of hyperemesis (severe nausea during pregnancy)
2022     NIHR Health Technology Assessment programme A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     NIHR Health Technology Assessment programme A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021     Health Technology Wales (HTW) Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021     NIHR Health Technology Assessment programme Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021     Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021     Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
2021     Center for Evidence-based Practice (CEP) Palliative care screening tools
2021     Center for Evidence-based Practice (CEP) Procalcitonin for antimicrobial discontinuation in hospitalized adult patients
2021     Center for Evidence-based Practice (CEP) Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2021     NIHR Health Services and Delivery Research programme Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021     Center for Evidence-based Practice (CEP) COVID-19: thrombotic adverse events with adenovirus vaccines
2021     NIHR Health Technology Assessment programme Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) after coronary interventions in the UK: a population based cohort study The ADAPTT Study
2021     NIHR Health Technology Assessment programme High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021     NIHR Health Technology Assessment programme EMPOWER: Early Signs Monitoring to Prevent Relapse and PrOmote Wellbeing, Engagement and Recovery
2021     Norwegian Institute of Public Health (NIPH) [Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]
2021     NIHR Health Technology Assessment programme A tailored, psychological intervention for mild to moderate anxiety or depression in people with chronic obstructive pulmonary disease(COPD) (TANDEM Tailored intervention for ANxiety and DEpression Management in COPD)
2021     Norwegian Institute of Public Health (NIPH) [Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2021     NIHR Health Technology Assessment programme High Or Low Dose Syntocinon for delay in labour (HOLDS)